Covid-19 roundup: India moves forward with review of Pfizer and AstraZeneca vaccine candidates; China's Sinovac gets $515M to double vaccine production
Less than a week after Pfizer and BioNTech landed a historic authorization for their Covid-19 vaccine in the UK, India is speeding up its own review of the candidate and another from AstraZeneca, an unnamed source told Reuters.
AstraZeneca submitted its application for emergency use approval in India on Monday, Reuters reported, while Pfizer filed over the weekend. Mass supply will be handled by the Serum Institute of India, the world’s largest vaccine producer by volume.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.